M&A Insider




Merger Arbitrage

Company Ticker Acquirer Announced Date Deal Price Current Price Spread Expected Close
Benihana BNHN Angelo, Gordon & Co. 5/22/2012 $16.30 $16.13 1.1% 12/31/2012
Ariba ARBA SAP AG 5/22/2012 $45.00 $45.22 -0.5% 9/30/2012
Edgar Online EDGR RR Donnelley 5/22/2012 $1.09 $1.07 2.1% 9/30/2012
Cooper Industries CBE Eaton 5/21/2012 $72.70 $71.28 2% 12/31/2012
Pansoft Company PSOF Timesway Group Limited 5/17/2012 $4.15 $3.96 4.8% N/A
Cost Plus CPWM Bed Bath & Beyond 5/9/2012 $22.00 $21.99 0% 9/30/2012
GTSI Corp. GTSI UNICOM 5/7/2012 $7.75 $7.74 0.1% 6/30/2012
Kensey Nash KNSY Royal DSM 5/3/2012 $38.50 $38.52 -0.1% 9/30/2012
Standard Microsystems SMSC Microchip Technology 5/2/2012 $37.00 $36.55 1.2% 9/30/2012
Charming Shoppes, Inc. CHRS Ascena Retail Group, Inc. 5/2/2012 $7.35 $7.33 0.3% 6/30/2012

See All

Highlighted Deal

On April 23, 2012, AstraZeneca (NYSE: AZN) and Ardea Biosciences, Inc. (Nasdaq: RDEA) entered into a definitive merger agreement, pursuant to which AstraZeneca will acquire Ardea, a San Diego, California-based biotechnology company focused on the development of small-molecule therapeutics. Ardea’s clinically most advanced product candidate, lesinurad (formerly known as RDEA594), is currently in Phase III development as a potential treatment for the chronic management of hyperuricaemia in patients with gout.

Under the terms of the agreement, AstraZeneca will acquire Ardea for $32 per share which represents a total cash value of approximately $1.26 billion, including existing cash. This represents a premium on the value of Ardea’s stock of 50% based on the one month volume-weighted average price (VWAP) and 54% based on the closing price on Friday, 20 April 2012... More